Financings Of The Fortnight Sees A Venture Capital Trend: Identify And Bring In The Buyer Early
This article was originally published in The Pink Sheet Daily
Plus news on recent financings by Ember Therapeutics, Aviir, Covidien and Ariad Pharmaceuticals.
You may also be interested in...
Covidien says it has been working for several years toward separating out its pharma business from its larger and more profitable devices/supplies division.
Collaboration will create start-up biotechs to advance promising research in orphan indications, but the companies will not take a “cookie cutter” approach to structure or evolution.
Atlas Venture and OrbiMed Advisors have launched a virtual company to support development of a single asset, which Lilly can buy back after a Phase II trial.